Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vectorite Biomedical's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 37.52.
Vectorite Biomedical's Days Inventory for the
six
months ended in Dec. 2025 was 145.24.
Vectorite Biomedical's Days Payable for the
six
months ended in Dec. 2025 was 10.77.
Therefore, Vectorite Biomedical's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 171.99.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Vectorite Biomedical Cash Conversion Cycle Related Terms
Vectorite Biomedical Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Vectorite Biomedical's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4170 vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Vectorite Biomedical's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vectorite Biomedical Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vectorite Biomedical's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Vectorite Biomedical's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Vectorite Biomedical's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vectorite Biomedical (ROCO:4170) has a Cash Conversion Cycle of 171.99 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Vectorite Biomedical and its competitors.
Is Vectorite Biomedical's Cash Conversion Cycle too high?
Vectorite Biomedical's current Cash Conversion Cycle is 171.99. The Biotechnology industry median Cash Conversion Cycle is 103.69. Vectorite Biomedical's value of 171.99 is 65.9% above this industry median. Overall, Vectorite Biomedical has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vectorite Biomedical's Cash Conversion Cycle compare to VRTX and REGN?
Vectorite Biomedical's Cash Conversion Cycle of 171.99 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 103.69. Vectorite Biomedical's value of 171.99 is 65.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 103.69, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vectorite Biomedical's current Cash Conversion Cycle of 171.99 is 65.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Vectorite Biomedical and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 103.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vectorite Biomedical's current Cash Conversion Cycle is 171.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectorite Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Vectorite Biomedical (ROCO:4170) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$17.57, compared to a current price of NT$12.50 — trading 28.9% below its estimated fair value. The current Cash Conversion Cycle is 171.99 and 65.9% above the Biotechnology industry median of 103.69. Vectorite Biomedical's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Vectorite Biomedical (ROCO:4170), the current Cash Conversion Cycle is 171.99 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vectorite Biomedical (ROCO:4170) Overvalued in 2026?
Based on GuruFocus' analysis, Vectorite Biomedical stock appears to be undervalued.
The current stock price of NT$12.50 is trading 28.9% below its estimated GF Value™ of NT$17.57.
GuruFocus considers Vectorite Biomedical to be Modestly Undervalued.
Key valuation signals for ROCO:4170:
Cash Conversion Cycle: 171.99
GF Value™: NT$17.57 vs. price of NT$12.50 (28.9% below fair value)
Industry Position: 65.9% above the Biotechnology median
No single metric tells the full story. See the ROCO:4170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vectorite Biomedical Inc is a Taiwan-based biotechnology research and development, cell product (preparation) manufacturing and immune cell collection and storage business.
65GF Score
Get the complete analysis for ROCO:4170
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4170 has been successfully added to your 
